Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma (NCT01534078)
Brentuximab vedotin is an antibody-drug conjugate or ADC, which is the combination of an antibody (a protein that binds to cells) and a chemotherapeutic molecule. The drug works by using the antibody portion to enter into the Hodgkin lymphoma (HL) cells and then releasing the chemotherapy portion, which attempts to destroy the cell.
The intravenous chemotherapy drugs Adriamycin® , Vinblastine and Dacarbazine (also known as AVD) which you will receive in this research study are approved for use in people with Hodgkin lymphoma. A drug called bleomycin is usually included with AVD, but since it appears to be a less effective drug with significant potential risks, it is being replaced in this study with the drug brentuximab vedotin.
In this research study, the investigators are looking to see whether brentuximab in combination with AVD is effective in treating limited-stage Hodgkin Lymphoma.
This trial is sponsored by Massachusetts General Hospital. 
- Condition: Hodgkin Lymphoma
- Phase: II
- Enrollment: 34
- Start: March 2012
- Estimated Primary Completion: April 2015
- Last verified: October 2014
Last Editorial review: July 15, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.